Molecular Theranostics, LLC

2:00 PM - 2:15 PM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Molecular Theranostics, LLC (MT or the Company) was formed in January 2014 in the state of Ohio. The goal of the company is development and commercialization of innovative imaging agents for the accurate detection and characterization of aggressive tumors. Specifically, we have developed a targeted MRI contrast agent (MT218) and a PET probe (MTP219) specific to an oncoprotein in tumor microenvironment. The efficacy of the imaging agents has been demonstrated in different tumor models, including breast cancer, liver cancer, pancreatic cancer, and prostate cancer. The imaging agents are effective to provide early detection of small aggressive solid tumors and able to differentiate aggressive tumors from benign tumors and tissues. The pre-clinical GLP safety data showed the safety of MT218. Clinical application of these imaging agents has great promise to provide much needed assistance to the physicians for precision cancer management
Company Type:
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
MRI agent MT218, PET agent MTP219
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided